Objective: Osteoarthritis (OA) is polygenic with over 90 independent genome-wide association loci so far reported. A key next step is the identification of target genes and the molecular mechanisms through which this genetic risk operates. The majority of OA risk-conferring alleles are predicted to act by modulating gene expression. DNA methylation at CpG dinucleotides may be a functional conduit through which this occurs and is detectable by mapping methylation quantitative trait loci, or mQTLs. This approach can therefore provide functional insight into OA risk and will prioritize genes for subsequent investigation. That was our goal, with a focus on the largest set of OA loci yet to be reported. Method: We investigated DNA methylation, genotype and RNA sequencing data derived from the cartilage of patients who had undergone arthroplasty and combined this with in silico analyses of expression quantitative trait loci, epigenomes and chromatin interactions. Results: We investigated 42 OA risk loci and in ten of these we identified 24 CpGs in which methylation correlated with genotype (false discovery rate (FDR) P-values ranging from 0.049 to 1.73x10 À25 ). In silico analyses of these mQTLs prioritised genes and regulatory elements at the majority of the ten loci, with COLGALT2 (encoding a collagen galactosyltransferase), COL11A2 (encoding a polypeptide chain of type XI collagen) and WWP2 (encoding a ubiquitin ligase active during chondrogenesis) emerging as particularly compelling target genes.
Introduction
Genetic susceptibility is a major risk factor for osteoarthritis (OA) 1, 2 . Genome-wide association studies (GWAS) have revealed the polygenic nature of OA and to date over 90 independent risk loci have been identified 3e6 . The largest and most recent OA GWAS was carried out using the full UK Biobank cohort, with a focus on hip and knee OA 6 . This study utilised the genotypes of up to 455,000 individuals across 17.5 million single nucleotide polymorphisms (SNPs). Meta-analysis with the arcOGEN dataset 7 resulted in 64 genome-wide significant loci, 52 of which were novel. A series of techniques including statistical FINEMAPPING and expression quantitative trait locus (eQTL) co-localisation were employed to identify putative effector genes at these loci. DNA methylation at CpG dinucleotides is an epigenetic process that regulates gene expression 8 . Using the Illumina 450 genomewide methylation array, we have shown previously that changes in DNA methylation levels occur in cartilage chondrocytes and that these changes correlate with SNP genotype at around 25% of OA genetic risk loci 9, 10 . These CpGs are known as methylation quantitative trait loci, or mQTLs. At several OA loci, including GDF5 and RUNX2, genotype at the associated SNP correlates not only with DNA methylation but also with gene expression 11, 12 . This indicates that chondrocytes use DNA methylation as an intermediary between genotype and phenotype, with this epigenetic mechanism underpinning a large proportion of OA disease risk. Identifying mQTLs therefore offers insight into the functional mechanism of OA genetic susceptibility. Furthermore, if mQTL CpGs cluster in or close to a particular gene at a risk locus, their mapping prioritises that gene and functional regulators of the gene for further investigation as plausible effectors of the association signal.
In this current study, we focussed on the OA signals that emerged from the analysis of the full UK Biobank cohort 6 and searched our cartilage genetic and epigenetic datasets to identify novel OA mQTLs. We were able to investigate a total of 42 signals and found evidence of mQTLs at ten of these. We subsequently carried out an in-silico analysis on these signals, highlighting regulatory elements and their putative gene targets requiring detailed functional analyses.
Methods mQTL analysis of OA risk loci
Genotype and DNA methylation data were generated previously using the Human Omni Express array and Infinium HumanMethylation450 array (Illumina) 9 . Both datasets were generated from 87 patients who had undergone joint arthroplasty for knee OA (n ¼ 57), hip OA (n ¼ 14), or neck-of-femur (NOF) fracture (n ¼ 16).
We used genotype at the UK Biobank GWAS SNP, or, if not captured, genotype at a proxy variant. Proxies were derived from European population data using the LDproxy tool 13 . The proxy with the highest r 2 relative to the GWAS SNP was chosen. At each locus, we investigated DNA methylation 1 Mb upstream and 1 Mb downstream of the association SNP. Linear regression was used to measure the relationship between methylation b-values (ranging from 0 to 1) and genotype (0, 1 or 2 copies of the minor allele) at the SNP. If the minor allele frequency (MAF) was low (<3 homozygotes in our cohort) we combined minor allele homozygotes with heterozygotes and compared these to major allele homozygotes.
RNA-sequencing (RNA-seq)
Hip cartilage RNA-seq data that we had generated previously was used to assess differential expression in genes of interest at each locus. Detailed analytical methods can be found within the original reports of this dataset 14e16 .
In silico eQTL analysis
For each locus that had an mQTL, we determined which genes at the locus were expressed in cartilage using our RNA-seq data (TPM>1). We then assessed whether any of these cartilageexpressed genes had an eQTL for the relevant association SNP by searching the genotype-tissue expression database GTEx (https:// www.gtexportal.org/home/).
In silico epigenome analysis and investigation of chromatin interactions

ROADMAP
(http://www.roadmapepigenomics.org/) was searched for epigenomic data, including chromatin state and presence of enhancers, at signals harbouring an OA mQTL. We focussed on five cell types of relevance to the articulating joint: E006, embryonic stem cell derived mesenchymal stem cells (MSCs); E049, bone marrow derived cultured chondrocytes; E023, MSC derived adipocytes; E025, adipose derived MSCs; E026, bone marrow derived MSCs. We searched the WashU epigenome browser 17 to identify long range chromatin interactions extending from annotated regulatory elements containing CpGs of interest. All publicly available HiC and long-range chromatin interaction datasets were loaded for all cell types with available data and the region was searched visually to identify interactions stemming from the regulatory elements. The human breast cancer cell line MCF7 and chronic myeloid leukaemia cell line K562 interaction schema represent protein factor mediated chromatin interaction data measured by RNA polymerase-II Chromatin Interaction Analysis with Paired-End Tag (PolII ChIA-PET) data 18 . These data were produced as part of the ENCODE project. Data from the human lymphoblastoid cell line GM12878 were produced by RNA CTCF ChIA-PET 19 .
Statistical analyses
All mQTL calculations were performed using Matrix eQTL 20 . In this analysis we investigated DNA methylation at 19,761 CpGs in correlation with genotype at 42 SNPs and the P-values were adjusted to account for the 19,761 tests performed using a false discovery rate (FDR) estimation based on BenjaminieHochberg correction 21 . Differential expression analysis between OA and NOF RNA-seq data was carried out with the Bioconductor package DESeq2 22 . Hypothesis testing was performed using the DESeq2 implementation of the Wald test and P-values were adjusted accordingly.
Results
OA loci investigated
The UK Biobank GWAS identified 52 novel OA association signals 9 . We excluded two of these as a SNP identification number was not reported. We excluded a further five as the SNP MAF was 5% or less, which would preclude us from having an adequate number of minor-allele carriers to test for mQTLs in our 87 patients. Of the remaining 45 loci, eight were not directly genotyped on our array and also lacked a proxy variant in high LD (r 2 > 0.7); these were also excluded. This left 37 of the 52 novel loci that could be analysed by us. In addition to novel loci, the authors of the UK Biobank GWAS also reported on previously identified OA signals. For four of these, the association SNP in their GWAS was in modest LD (r 2 < 0.7) with the SNP that had originally been reported as associated with OA, which may indicate a separate and novel signal. We therefore included these in our analysis. These are the SNPs rs10974438 (GLIS3), rs2396502 (RUNX2), rs2820443 (TGFB2) and rs4775006 (ALDH1A2). The authors also reported an association to rs12901372, a SMAD3 SNP that had previously shown suggestive evidence of association to OA. We also included this SNP. In total therefore, we analysed 42 loci; 37 novel and five previously reported (Supl. Table 2 ).
Identification of OA mQTLs
At each locus, we searched for correlations between genotype and methylation at all CpGs within a 2 Mb region flanking the association SNP. In total, we analysed methylation at 19,761 CpGs across the 42 loci (Supl. Table 3 ). This identified ten loci at which there was a significant correlation (FDR P-value <0.05) between genotype and methylation at one or more CpGs (Supl. Table 2 ). There were 24 such CpGs in total, with the largest number (nine) occurring at locus 10. Stratification by joint site, sex, and status (OA or NOF) did not identify any additional mQTLs. Below we discuss the results of each locus including the in-silico analyses.
Locus 1
rs11583641 (C>T, OA risk allele ¼ C, MAF ¼ 0.17) is located at chromosome 1q25.3. The SNP is not on our genotyping array and we therefore used the proxy rs10911472 (r 2 ¼ 0.99) and investigated 291 CpGs at this locus. Genotype at rs10911472 correlated with methylation at one CpG, located 6 kb from the association SNP: cg18131582 (FDR P ¼ 0.0027; Table I ). Both the SNP and CpG are located within the gene body of COLGALT2 [ Fig. 1(A) ]. The region encompassing cg18131582 is marked as an enhancer in multiple relevant cell types in ROADMAP [ Fig. 1(B) ]. The region containing the CpG was also marked as an area of DNaseI hypersensitivity and contained binding sites for multiple transcription factors [ Fig. 1(B) ]. The OA risk C allele corresponded with decreased levels of methylation [ Fig. 1(C) ]. GTEx revealed one eQTL corresponding to genotype at the association signal; a COLGALT2 eQTL in adrenal gland tissue, with the C allele correlating with a relative increase in gene expression. Our cartilage RNA-seq data showed a significant increase in COLGALT2 expression in OA compared to NOF controls (P ¼ 8.43x10
À8 , Fig. 1(D) ). Long range chromatin interactions were identified between the enhancer region containing cg18131582 and sequences towards the 3 0 untranslated region (3 0 UTR) of COLGALT2 in K562 cells [Supl. Fig. 1 . GTEx identified eQTLs across multiple tissue types for several cartilage-expressed genes at this locus. There was a significant increase in expression in OA of three of these:
Locus 4
rs9277552 (C>T, OA risk allele ¼ C, MAF ¼ 0.22) is located on chromosome 6p21.32. The SNP is not on our array and we therefore used the proxy rs9277557 (r 2 ¼ 0.81) and investigated 3,574 CpGs.
Genotype at rs9277557 correlated with methylation at four CpGs: cg25491704, cg02197634, cg02375585 and cg13921245 (FDR Pvalues of 0.0021, 0.011, 0.028 and 0.040, respectively; Table I ). These span a 42 kb region on chromosome 6 and flank the association SNP [ Fig. 3(A) ]. This is a gene-rich region coding for HLA and non-HLA genes, including COL11A2.
The OA risk allele correlated with an increase in methylation at cg02375585 but a decrease in methylation at cg02197634, cg25491704 and cg13921245 [ Fig. 3(C) ]. These latter three CpGs fall within the gene body of HLA-DPB1, with cg02197634 and cg25491704 being only 4bp apart [ Fig. 3(B) ]. These two CpGs are located within an intron of HLA-DPB1 and in the promoter region of the syntenic gene HLA-DPA1, with this promoter demonstrating long range chromatin interactions with the 3 0 UTR of HLA-DPB1 [Supl. Fig. 1(B) ]. This region is also one of DNase I hypersensitivity and transcription factor binding, with cg02197634 and cg25491704 being located within the binding site of POLR2A, the largest subunit of the eukaryotic mRNA synthesising enzyme RNA polymerase II.
cg02375585 is located within an intron of HLA-DPB2, which is a part of a repressed heterochromatic sequence that physically interacts with the promoter of COL11A2 [ Fig. 3 (A) and Supl. Fig. 1(C) ]. GTEx identified eQTLs across several tissue types for four cartilage- expressed genes at this locus: HLA-DPA1, HLA-DPB1, COL11A2 and HSD17B8. There was a significant increase in expression of COL11A2 in OA cartilage (P ¼ 7.7x10 À5 ; Fig. 3(D) ).
Locus 5
rs60890741 (C>CA, OA risk allele ¼ C, MAF ¼ 0.18) is located on chromosome 8q24.2 and marks a region of LD spanning 24.5 kb rs60890741 is not on our array and we therefore used the proxy rs12542856 (r 2 ¼ 0.97) and analysed 166 CpGs. We identified a single CpG, cg18170545, at which methylation significantly correlated with genotype at rs12542856 (FDR P ¼ 0.049; Table I ). This CpG falls within an intron of ASAP1 [Supl. Fig. 3(A) ] in a predicted enhancer region containing multiple transcription factor binding sites [Supl. Fig. 3(B) ]. The CpG is hypermethylated in cartilage, with the OA risk allele correlating with increased methylation [Supl. Fig. 3(C) ]. There were no cartilage-expressed genes at this locus that had GTEx eQTLs.
Locus 6
rs317630 (C>T, OA risk allele ¼ T, MAF ¼ 0.23) is located on chromosome 12q15 and falls within an intron of CPSF6 [Supl. Fig. 4(A) ]. rs317630 is not on our array and we therefore used the proxy rs317646 (r 2 ¼ 0.99) and analysed 239 CpGs.
We identified a single CpG, cg22375663, at which methylation significantly correlated with genotype at rs317646 (FDR P¼4.18x10 À11 ; Table I ). This CpG is intergenic, located 88 kb upstream of the association SNP and falls within a region marked as a bivalent enhancer and promoter [Supl. Fig. 4(B) ]. cg22375663 falls within the binding site for POLR2A. The OA risk allele correlates with an increase in methylation of the CpG [Supl. Fig. 4(C) ]. GTEx identified eQTLs across multiple tissue types for three cartilage-expressed genes at this locus: CPSF6, LYZ and YEATS4. There was no differential expression for any of these between OA and NOF cartilage [Supl. Fig. 4(D) ]. Expression of COLGALT2 in cartilage from OA and NOF patients. TPM, transcripts per million. Bars represent the mean and the SEM. P-values were calculated using a Wald test within the DESeq2 package.
Locus 7
rs35206230 (C>T, OA risk allele ¼ T, MAF ¼ 0.24) is located on chromosome 15q24.1. rs35206230 is not on our array and we therefore used the proxy rs1378940 (r 2 ¼ 0.96) and analysed 761
CpGs. Genotype at rs1378940 correlated with methylation at two CpGs, cg20040747 and cg10253484 (FDR P-values of 0.0027 and 0.028, respectively; Table I ). cg20040747 is located within an intron of SEMA7A [ Fig. 4(A) ] within a DNaseI hypersensitive enhancer region containing transcription factor binding sites [ Fig. 4(B) ]. cg10253484 is located 451 kb downstream of cg20040747, within the promoter region of SCAMP2 [ Fig. 4(B) ]. Chromatin interactions were identified between this promoter and that of the neighbouring gene MPI [Supl. Fig. 1(D) ]. The OA risk is associated with a decreased methylation of cg20040747 but an increased methylation of cg10253484 [ Fig. 4(C) ].
GTEx identified eQTLs at nine cartilage-expressed genes from within this locus: CSK, LMAN1L, ULK3, SCAMP2, MPI, FAM219B, RPP25, SCAMP5 and PPCDC. There was no differential expression for any of these between OA and NOF cartilage [ Fig. 4(D) ]. GTEx identified eQTLs at five cartilage-expressed genes at this locus: CLEC18A, IL34, NFAT5, NOB1 and PDXDC2P. There was a significant increase in expression of CLEC18A in OA cartilage (P ¼ 0.02; Fig. 5(D) ).
Locus 9
rs2953013 (T>G, OA risk allele ¼ G, MAF ¼ 0.32) is located on chromosome 17q11.2. This SNP was directly genotyped on the array and we analysed 313 CpGs. Genotype at rs2953013 correlated with methylation at one CpG, cg16779580 (FDR Horizontal lines represent the mean and SEM. 0, major allele homozygote; 1, heterozygote; 2, minor allele homozygote. (C) Expression of genes at the locus in cartilage from OA and NOF patients. TPM, transcripts per million. Bars represent the mean and the SEM. P-values were calculated using a Wald test within the DESeq2 package. P ¼ 0.006; Table I ). cg16779580 resides within RAB11FIP4 [Supl. Fig. 5(A) ] and specifically within an intronic enhancer region of the gene [Supl. Fig. 5(B) ], with the OA risk allele correlating with decreased methylation of the CpG [Supl. Fig. 5(C) ]. GTEx identified eQTLs at three cartilage-expressed genes at this locus: NF1, EV12A and RAB11FIP4. A significantly increased expression of RAB11FIP4 was observed in OA cartilage (P ¼ 0.05; Supl. Fig. 5(D) ).
Locus 10
rs62063281 (T>C, OA risk allele ¼ C, MAF ¼ 0.22) is located on chromosome 17q21.31. This SNP was not directly genotyped on the array and we therefore used the proxy rs17650901 (r 2 ¼ 0.98) and analysed 501 CpGs. Genotype at rs17650901 correlated with methylation at nine CpGs, with FDR P-values ranging from 0.037 to 1.73x10 À25 (Table I) . The nine positive CpGs demonstrate hypo-and hypermethylation, with the OA risk allele correlating with increased and decreased levels of methylation [ Fig. 6(C) ]. Several of the CpGs reside within genes and within potential functional domains [ Fig. 6(A) ] with four meriting particular comment. cg11117266 and cg16520312, which are located just 10bp apart, fall within the promoter region of MAPT [ Fig. 6(B) ], whilst cg15633388 and cg23616531 are located within the promoter region of KANSL1 and an adjacent enhancer element [ Fig. 6(C) ]. These regulatory elements of MAPT and KANSL1 physically interact with each other [Supl. Fig. 1(E) ], implying coordinated functionality of DNA sequences harbouring the four CpGs. GTEx identified eQTLs for 19 cartilage-expressed genes at this locus, including MAPT and KANSL1 [ Fig. 6(D) ]. Four showed a significant differential expression between OA and NOF cartilage, with NMT1 (P ¼ 3.30x10 À3 ) and PLEKHM1 (P ¼ 6.05x10 À10 ) demonstrating reduced expression in OA, and CRHR1 (P¼0.03) and KANSL1-AS1 (P ¼ 0.01) demonstrating increased expression.
Discussion
GWAS are widely used in the identification of risk-conferring variants in a range of complex traits. Despite this, there remains an enormous disparity between the discovery of GWAS signals and subsequent functional analyses, which are essential in their interpretation and the identification of intervenable targets 23 . In this report, we utilised genome wide genetic and epigenetic datasets and discovered cis mQTLs operating at novel OA risk loci. This highlights the potential mechanistic importance of DNA methylation in mediating gene expression. This study aims to bridge the gap between GWAS and the execution of successful functional analyses, by prioritising disease-associated regulatory elements and genes. There have now been 18 OA mQTLs identified to date. This is likely a conservative number considering the low genomic coverage of the Illumina methylation array, which captures less than 1% of CpGs. Our results emphasise the key function of DNA methylation in mediating a large proportion of OA susceptibility. Due to the joint specificity of both the cartilage methylome and OA GWA signals, we found it somewhat surprising that we did not identify any hip-or knee-specific mQTLs. However, this is consistent with our previous analyses 9, 10 . We hypothesise that, whilst OA mQTLs are active at both joint sites, they might not necessarily exert a functional effect at all sites due, perhaps, to variability in chromatin state, or distinct compensatory mechanisms within a joint. Additionally, it is feasible that the enhancers marked by mQTLs are functionally active during different stages of the lifespan and could be integral for correct cartilage development and maintenance within the joints at distinct time points. At each novel mQTL we analysed cartilage RNA-seq data and online datasets, including eQTL and long-range chromatin interaction data, to highlight functionally relevant genes and regulatory elements that could be the targets of OA genetic risk. In this regard, loci 1, 4 and 8 were particularly compelling. At locus 1, (rs11583641, C>T), cg18131582 falls within a predicted COLGALT2 enhancer. There is a physical interaction between this enhancer and the body of the gene, which implies that the enhancer could regulate COLGALT2 expression. The gene encodes procollagen galactosyltransferase 2, an enzyme that posttranslationally glycosylates collagen 24 . Collagens are core structural and functional components of the cartilage extracellular matrix (ECM) with their post-translational modification being key to their activity 25 . Polymorphism in COLGALT2 has previously been associated with skeletal development 26 whilst in our RNA-seq data, there was a highly significant increased expression of the gene in OA hip cartilage. This increase in COLGALT2 expression has also been observed in knee cartilage 27 . In a recent study of the OA cartilage transcriptome performed on a Netherlands cohort of 47 patient samples 28 , evidence of allelic expression imbalance at COLGALT2 was reported, implying that the gene is subject to cartilage eQTLs. We hypothesise that in OA there is an attempted reparative response of the cartilage involving new collagen synthesis with a concurrent upregulation of COLGALT2. This increased expression requires methylation of the enhancer falling within the gene body of COLGALT2. However, the OA risk allele attenuates this response, manifested as lower enhancer methylation and an inadequate increase in COLGALT2 expression. This ultimately has a negative impact on the post-translational modification of newly synthesised collagens, hindering repair.
At locus 4, (rs9277552, C>T), there were four mQTL CpGs, three within HLA-DPB1 and one within HLA-DPB2. The HLA-DPB2 CpG, cg02375585, marks a heterochromatic region that interacts with the promoter of COL11A2. This gene encodes the a2 polypeptide chain of type XI collagen, a critical structural component of articular cartilage. Type XI collagen is essential for the stability of type II collagen fibrils, which comprise 90% of the collagen network of the cartilage ECM 29 . Mutations in COL11A2 cause Stickler syndrome, a skeletal abnormality that often presents with early-onset OA 30 . In our RNA-seq data, COL11A2 is abundantly expressed with a highly significant increased expression in OA vs non-OA cartilage. Similarly, a significant increase in COLL11A2 expression was detected in OA knee cartilage 27 . This may reflect a cartilage reparative response. Unfortunately, the HLA locus was excluded from analysis in the Netherlands cartilage transcriptome study 28 . On GTEx, the OA riskconferring C allele of rs9277552 correlates with both increased and decreased expression of the gene in non-cartilaginous tissues. We speculate that in cartilage, this risk conferring allele will also correlate with differential expression of the gene and that akin to COLGALT2, this expression change is mediated by differential enhancer methylation. At locus 8, (rs6499244, A>T), there were two mQTL CpGs, both located in an enhancer within WWP2. This gene encodes NEDD4-like E3 ubiquitin-protein ligase, a protein that is expressed at high abundance in cartilage and which plays an essential role in chondrogenesis via TGFb/Smad signaling 31 . Knockout of the protein results in altered craniofacial patterning and palatogenesis 32, 33 . In our search of GTEx, we did not find any WWP2 eQTLs correlating with the OA association signal and there was no differential expression of the gene between our OA and non-OA cartilage (data not shown). However, the Netherlands cartilage transcriptome study reported allelic expression at the gene 27 . The transcript SNPs used are in modest LD with the association SNP, with the most significant WWP2 transcript SNP, rs1052429 (A/G), having an r 2 of only 0.22 with rs6499244. Despite this, the OA risk conferring A allele of rs6499244 occurs almost exclusively on a haplotype containing the A allele of rs1052429, which correlates with increased WWP2 expression. We therefore hypothesise that the risk allele at this locus leads to increased methylation of the enhancer and subsequent increased expression of WWP2, which is detrimental to cartilage health. WWP2 encompasses microRNA 140, which also regulates chondrocyte activity 34 and could also be a target of this mQTL.
The locus with the largest number of significant CpGs in our study was locus 10, with nine including three with FDR P-values <1.0x10
À15 . This is an extremely complex locus of very high LD containing a large number of polymorphisms. These span an interval of 945 kb and contain at least nine recently evolved common haplotypes, including inversions and repeats 35 . The large number of highly significant CpGs at this locus, which are spread across a number of genes, many of which are expressed in cartilage, make this a highly intriguing signal. None of the 19 cartilage-expressed genes at the locus that have eQTLs in GTEx were reported as demonstrating allelic expression in the Netherlands cartilage transcriptome study. However, this could simply reflect the relatively modest sample size used in that transcriptome report. Future functional studies of this complex locus may require a gene by gene approach.
In summary, we have identified novel mQTLs correlating to genotype at OA risk loci. Through this analysis, we have more than doubled the number of such mQTLs and in several instances, we have highlighted putative effector genes through the colocalisation of CpGs to regulatory elements; COLGALT2, COL11A2 and WWP2 represent clear examples. Our results reveal potential mechanisms by which the OA-encoded risk at several of the loci mediate their effect and as such, the significant CpGs and their regulatory elements, and putative target genes now warrant a detailed functional investigation in the context of OA molecular aetiology.
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